Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 263

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 263
---
 brief periods of time in restricted geographical areas, and only when the employee has obtained unique value to the employer specific to that employer’s business and not just regarding the professional development of the employee. If it is not able to enforce non -competecovenants, it may be faced with added competition. 103 EXTRAORDINARY SHAREHOLDER MEETING OF NLS General NLS is furnishing this proxy statement/prospectus to NLS’s shareholders as part of the solicitation of proxies by the NLS Board for use at the NLS Meeting to be held on August 25, 2025, and at any adjournment thereof. This proxy statement/prospectus provides NLS’s shareholders with information they need to know to be able to vote or instruct their vote to be cast at the NLS Meeting. Date, Time and Place The NLS Meeting will be held on August 25, 2025 at 4:00 p.m., local time, at the premises of Baker McKenzie Switzerland AG, Holbeinstrasse30, 8034 Zurich, Switzerland. You can participate in the NLS Meeting, vote and submit questions in person. Purpose of the NLS Meeting NLS and Kadimastem have entered into a Merger Agreement. In order to give effect to the Merger Agreement, NLS must fulfill various closing conditions. The compliance with certain closing conditions can only be effected by resolutions of the shareholders’ meeting, as these conditions are within the competence of the shareholders’ meeting. The Merger Agreement requires the NLS Meeting to approve the following resolutions: •Proposal No. 1 to approve the Merger Agreement. •Proposal No. 2 to approve the par value reduction, reverse split and ordinary share capital increase with contribution of the Kadimastem shares to implement the Merger. •Proposal No. 4 to approve the reinstatement of the capital band. •Proposal No. 6 to approve the conditional share capital for shareholders’ options. •Proposal No. 9 to approve the election of the new members to the NLS Board. •Proposal No. 13 to approve the CVR Agreement. •Proposal No. 14 to approve the conversion of outstanding options and RSUs issued by Kadimastem. Further agenda items are: •Proposal No. 3 to approve the ordinary share capital increase regarding the issuance of NLS Preferred Shares. •Proposal No. 5 to approve the conditional share capital for employee and advisory options. •Proposal No. 7 to approve the transfer and